| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenues | 45,250 | 0 | 3,729 | 3,385 |
| Research and development | 197 | 2,424 | 9,156 | 11,326 |
| General and administrative | 1,239 | 3,354 | 3,907 | 5,203 |
| Total operating expenses | 1,436 | 5,778 | 13,063 | 16,529 |
| Operating loss | 43,814 | -5,778 | -9,334 | -13,144 |
| Gain (loss) on sale of held for sale assets | 320 | -3,539 | - | - |
| Loss on abandonment of operating lease right-of-use asset | 0 | 927 | - | - |
| Interest income, net | - | - | 68 | 442 |
| Other income, net | 583 | 470 | - | - |
| Pre-tax income(loss) | 44,717 | -9,774 | -9,266 | -12,702 |
| Income tax expense | 0 | 0 | - | - |
| Net income(loss) | 44,717 | -9,774 | -9,266 | -12,702 |
| Comprehensive loss | - | - | - | -12,702 |
| Earnings per share, basic | 1.07 | -0.23 | -0.22 | -0.31 |
| Earnings per share, diluted | 1.07 | -0.23 | -0.22 | -0.31 |
| Weighted average number of shares outstanding, basic | 41,788,096 | 41,788,096 | 41,771,213 | 41,588,035,000 |
| Weighted average number of shares outstanding, diluted | 41,940,292 | 41,788,096 | 41,771,213 | 41,588,035,000 |
Carisma Therapeutics Inc. (CARM)
Carisma Therapeutics Inc. (CARM)